Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lonza and Integral Molecular announced a strategy to offer complementary expertise to their respective customers to better assess the risks of off-target binding of biologic drug candidates.
read more
Lonza announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion focused on extending the capabilities and capacity of development laboratories and kilogram-...
read more
Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third ADC produced at the site.
read more
Thursday, December 10, 2020
Lonza has announced an investment to expand its particle engineering and drug product capabilities at its Oregon site.
read more
Wednesday, December 02, 2020
Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa, Florida site.
read more
Tuesday, October 27, 2020
Lonza announced a $93m investment in its CHI Division, a dosage form delivery partner to the biopharma and health nutrition industry.
read more
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement. At scale, and following ...
read more
Lonza expanded the range of particle engineering services offered by its Monteggio (CH) site through the introduction of X-ray powder diffraction (XRPD).
read more
Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over $22 million, will allow Lonza to provide a smoother transition from small-scale to...
read more
Lonza announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation...
read more
Lonza is opening a dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies.
read more
Monday, November 19, 2018
Lonza Pharma & Biotech has opened its Collaborative Innovation Center (CIC) in the Haifa Life Science Park, Israel.
read more
Lonza has selected Rockwell Automation for the turnkey implementation of the Lonza strategic vision of bringing the digital factory to nine former Capsugel facilities that manufacture drug capsules.
read more
Following the recent FDA approval of the PAS for second-generation Andexxa, Portola and Lonza announce the start of supply of the recombinant coagulation factor from Lonza’s Porriño facility.
read more
Monday, December 10, 2018
Lonza announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou.
read more